Longer Telomeres Are Associated with Cancer Risk in MMR-Proficient Hereditary Non-Polyposis Colorectal Cancer

Nuria Seguí1, Elisabet Guinó2, Marta Pineda1, Matilde Navarro1, Fernando Bellido1, Conxi Lázaro1, Ignacio Blanco1, Víctor Moreno2,3, Gabriel Capellá1, Laura Valle1*

1 Hereditary Cancer Program, Catalan Institute of Oncology, IDIBELL, Hospitalet de Llobregat, Barcelona, Spain, 2 Unit of Biomarkers and Susceptibility, Catalan Institute of Oncology, IDIBELL and CIBERESP, Hospitalet de Llobregat, Barcelona, Spain, 3 Department of Clinical Sciences, Faculty of Medicine, University of Barcelona, Hospital de Llobregat, Barcelona, Spain

Abstract

Aberrant telomere length measured in blood has been associated with increased risk of several cancer types. In the field of hereditary non-polyposis colorectal cancer (CRC), and more particularly in Lynch syndrome, caused by germline mutations in the mismatch repair (MMR) genes, we recently found that cancer-affected MMR mutation carriers had shorter telomeres and more pronounced shortening of telomere length with age than controls and unaffected MMR gene mutation carriers. Here we evaluate blood telomere length in MMR-proficient hereditary non-polyposis CRC, i.e. familial CRC type X (fCRC-X). A total of 57 cancer-affected and 57 cancer-free individuals from 34 Amsterdam-positive fCRC-X families were analyzed and compared to the data previously published on 144 cancer-affected and 100 cancer-free MMR gene mutation carriers, and 234 controls. Relative telomere length was measured using a monochrome multiplex quantitative PCR method, following strict measures to avoid sources of bias and adjusting by age. Despite the retrospective nature of our study, the results show that longer telomeres associate with cancer risk in fCRC-X, thus identifying different patterns of telomere length according to the status of the MMR system.

Citation: Seguí N, Guinó E, Pineda M, Navarro M, Bellido F, et al. (2014) Longer Telomeres Are Associated with Cancer Risk in MMR-Proficient Hereditary Non-Polyposis Colorectal Cancer. PLoS ONE 9(2): e86063. doi:10.1371/journal.pone.0086063

Editor: Amanda Ewart Toland, Ohio State University Medical Center, United States of America

Received October 8, 2013; Accepted December 9, 2013; Published February 3, 2014

Copyright: © 2014 Seguí et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This work has been funded by the Spanish Ministry of Economy (State Secretariat for Research, Development and Innovation) (grants SAF2012-38885 to LV and SAF2012-33636 to GC; and Ramón y Cajal contract to LV); L’Oreal-UNESCO “For Women in Science”; the Scientific Foundation Asociación Española Contra el Cáncer; the Catalan Government (grant 2009SGR290); and Carlos III Health Institute (fellowship to NS). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: lvalle@iconcologia.net

Introduction

Family history is one of the strongest risk factors for the development of colorectal cancer (CRC) and is involved in approximately 20% of all CRC cases. However, only 2–6% of all CRCs are explained by germline mutations in known high-penetrance CRC genes. The Amsterdam criteria were defined to identify hereditary non-polyposis CRC cases, considering young age (<50 years) at cancer diagnosis and high familial aggregation of CRC (Amsterdam I) or other related tumors (Amsterdam II). Approximately 60% of the families that fulfill the Amsterdam criteria show DNA mismatch repair (MMR) deficiency as a consequence of a germline mutation or epimutation in a MMR gene, i.e. MLH1, MSH2, MSH6 or PMS2 (Lynch syndrome; LS). The remaining 40% do not show MMR defects and the genetic cause of the familial CRC aggregation is still unknown, having been grouped as familial CRC type X (fCRC-X) [1,2].

Chromosome telomeres consist of multiple short repeat (TTTAGG) that protect against large-scale genomic rearrangements. Telomeres shorten with cell division, eventually leading to cellular senescence. On rare occasions, cells that aberrantly bypass replicative senescence with critically short telomeres may develop genomic instability and potentially become tumorigenic. In cancer cells, however, as in stem cells, telomerase, the enzyme that adds telomeric repeats to the chromosome ends, is expressed, compensating for telomere erosion and preventing senescence/apoptosis [3–5].

Germline mutations in the components of the telomerase complex cause dyskeratosis congenita. Patients with this disorder have short telomeres, which lead to bone marrow failure and increased cancer risk [6]. Likewise, mouse models with telomerase deficiency and short telomeres have high risk of cancer [7]. Recent epidemiological studies have evaluated telomere length measured in peripheral blood DNA as a potential biomarker of cancer risk. Several studies have reported associations between telomere length and cancer risk, although the data are inconsistent among studies and tumor types [8]. In CRC studies, contradictory results have been observed, apparently due to differences in study population, study design, analytical approach, sample size, or exposure to environmental factors [9–15].

Regarding hereditary CRC, our group recently reported that cancer-affected MMR gene mutation carriers had shorter telomeres and showed faster telomere attrition with age, measured in blood, than controls and cancer-free MMR gene mutation carriers [16]. Nevertheless, the role of telomere length as cancer...
risk modifier in LS could not be asserted since it had been argued that the shortened telomeres observed in retrospectively collected samples from cancer-affected individuals might be a consequence of the disease [8,14]. However, the fact that cancer-free mutation carriers had longer telomeres than cancer-free controls provided additional evidence in support to the hypothesis that telomere length might act as a cancer risk modifier in LS [16].

Here we report the first study of the behavior of blood telomere length in MMR-proficient hereditary non-polyposis CRC, i.e. fCRC-X, and compare it to the behavior observed in controls and in hereditary non-polyposis CRC with a MMR defect, i.e. LS (previously published [16]).

Materials and Methods

Ethics Statement

Written informed consent was obtained from all subjects. The study was approved by the Ethics Committee of IDIBELL (ref. PR221/09).

Study Participants

A total of 114 individuals, 57 cancer-affected and 57 cancer-free, from 34 fCRC-X families were included in the study. These families fulfilled the Amsterdam criteria but did not show MMR defects (microsatellite instability or loss of expression of the MMR proteins MLH1, MSH2, MSH6 and PMS2). In all, 76.5% (26/34) of the families fulfilled Amsterdam I criteria and 23.5% (8/34) Amsterdam II. For comparative purposes, previously published telomere length data from individuals belonging to LS families and from controls were included in the analyses [16]. Familial CRC-X, LS and control samples were all of Caucasian origin and recruited from the same homogeneous population (the Spanish region of Catalonia) through the Hereditary Cancer Program of the Catalan Institute of Oncology, IDIBELL. Table 1 shows the characteristics of the fCRC-X cases studied, comparing them to the LS individuals and controls previously analyzed [16].

Relative Telomere Length Measurement

Relative telomere length (RTL) was assessed using a monochrome multiplex quantitative PCR method [17], under the same conditions as in Segui et al. [16]. Moreover, MMR-proficient hereditary cases were run together with LS cases and controls. In order to rule out artifacts or technical sources of variation, a standard curve was included in each run (384-well plate), each sample was assayed in triplicate, and whenever possible, equal numbers of samples from different clinical groups were run in the same plate. Storage and DNA extraction from peripheral blood were performed at the same facility and using the same extraction methods, as recommended for retrospective telomere length studies [9].

Statistical Analyses

RTL was adjusted by age based on the telomere length shortening occurring with age in the general population (controls), as previously reported [16,18]. Differences in age-adjusted telomere lengths were analyzed using the Wilcoxon rank sum test (Mann-Whitney U). The Kruskal-Wallis rank sum test was used to compare the demographic characteristics among groups. All tests were two-sided and p-values below 0.05 were considered statistically significant. The analyses were performed using R statistical software.

Results

Age-adjusted RTL was evaluated in 57 cancer-affected fCRC-X patients and 57 unaffected individuals from 34 fCRC-X families. The results were compared to the results we published in a previous study of 144 cancer-affected MMR gene mutation carriers, 100 unaffected MMR gene mutation carriers and 234 controls [16].

Cancer-affected fCRC-X cases showed significantly longer telomeres than unaffected fCRC-X individuals (p = 0.009) and cancer-free controls (p = 0.013) (Fig. 1). These results were in sharp contrast to those previously observed in LS, where telomere lengths detected in cancer-affected MMR gene mutation carriers were shorter than those in unaffected mutation carriers (p = 0.032) [16]. On the other hand, cancer-free fCRC-X cases showed shorter telomeres than cancer-free MMR gene mutation carriers (p = 0.015), but of similar length to controls (Fig. 1).

Discussion

We found that longer telomeres are associated with cancer in fCRC-X. Moreover, based on data previously published by our

Table 1. Characteristics of the hereditary non-polyposis CRC and control groups studied. Data on Lynch syndrome families and controls were published previously [16].

| | fCRC-X families (n = 34) | Lynch syndrome families (n = 96) | Controls | P-value |
|---|---|---|---|
| | Cancer | Cancer-free | MMR gene mutation carriers | Cancer | Cancer-free | |
| N | 57 | 57 | 144 | 100 | 234 | 0.037 |
| Median age at blood draw (± SD) | 56.0 (±13.9) | 50.0 (±20.3) | 51.5 (±13.4) | 35.0 (±11.5) | 42.0 (±14.9) |
| Sex: n (%) | M: 27 (47.4) | M: 28 (49.1) | M: 74 (51.4) | M: 40 (40.0) | M: 92 (39.3) | 0.968 |
| | F: 30 (52.6) | F: 29 (50.9) | F: 70 (48.6) | F: 60 (60.0) | F: 142 (60.7) |
| Median age at cancer diagnosis (± SD) | 49.0 (±13.4) | 43.0 (±12.9) | | | 0.278 |

N, number of subjects; SD, standard deviation; M, male; F, female.

1Cancer: Individuals affected with a LS-associated cancer: CRC and/or cancer of the endometrium, ovary, stomach, small bowel, hepatobiliary tract, pancreas, upper uroepithelial tract or brain.

2Controls include non-carriers from LS families (n = 144) and unrelated cancer-free controls (n = 90).

3Kruskal-Wallis rank sum test.

doi:10.1371/journal.pone.0086063.t001
group [16], MMR-deficient and -proficient non-polyposis hereditary cases show distinct patterns of blood telomere length, suggesting that the status of the MMR system is key in defining telomere length in hereditary cases.

Several epidemiological studies have investigated the association of telomere length with CRC risk in the general population, producing conflicting results [19]. Evidence from retrospective studies indicates that telomeres in peripheral blood cells are shorter in CRC cases than controls. However, this association has not been replicated in prospective studies, suggesting that the association between short telomeres and CRC in retrospective studies is somehow the result of disease, treatment or differential survival rather than the cause (effect of reverse causation) [14].

Regarding prospective studies, no association was found in three relatively small studies (134–191 cases vs. 306–406 controls) [9–11]. However, more recently, larger prospective studies found that longer telomeres were associated with higher CRC risk (cases/controls = 2,157/3,921) [14], or that both long and short telomeres increased CRC risk (cases/controls = 441/549) [15].

Figure 1. Age-adjusted RTL in subjects belonging to fCRC-X and LS families. The different groups correspond to: cancer-affected fCRC-X cases (median age-adjusted RTL: 0.017); cancer-free individuals from fCRC-X families (median: −0.215); cancer-affected MMR gene mutation carriers (median: −0.131); cancer-free MMR gene mutation carriers (median: −0.079); and cancer-free controls (median: −0.092). Differences in age-adjusted RTL were analyzed using the Wilcoxon rank sum test (Mann-Whitney U). The boxes represent the interquartile range of distributions (25th and 75th percentiles); the horizontal lines within the boxes, the medians; and the vertical lines, the 5th and 95th percentiles. Data from LS families and controls were published previously [16].

doi:10.1371/journal.pone.0086063.g001

Despite the retrospective nature of our study, we found that cancer-affected fCRC-X individuals had longer telomeres than cancer-free members of the same type X families, controls, and cancer-affected members of LS families (MMR gene mutation carriers). Therefore, longer telomeres are associated with cancer risk in MMR-proficient hereditary non-polyposis CRC, as observed in large prospective population-based CRC series [14,15]. Further studies assessing telomere length before and after cancer diagnosis in fCRC-X cases will be crucial to demonstrate the precise effect of cancer on blood telomere length in this group of patients.

Previous evidence supports the hypothesis that long telomeres might increase cancer risk: first, long telomeres may delay cellular
senescence and apoptosis, increasing the chance that genetic abnormalities will accumulate [3,20]; secondly, a subset of colorectal tumors has longer telomeres than the adjacent non-tumor colon mucosa [21]. Telomere length assessment in iCRC-X tumors will provide additional insight into whether MMR-proficient hereditary tumors also have elongated telomeres. Similarly, knowing the levels of telomerase expression or of enzymatic activity in peripheral blood and tumor samples might aid the design of specific therapeutic and/or preventive approaches. The identification of cancer risk alleles, such as those with cancer risk modifiers, might lead to the discovery of new biomarkers and prevention strategies. In conclusion, in contrast to the observations for LS but in line with the results of large CRC prospective studies, elongated telomeres are associated with increased cancer risk in Amsterdam-positive MMR-proficient hereditary non-polyposis CRC.

**Author Contributions**

Conceived and designed the experiments: LV NS. Performed the experiments: NS LV. Analyzed the data: EG NS LV VM. Contributed reagents/materials/analysis tools: MP MN FB CL IB GC. Wrote the paper: LV NS. Critically revised the manuscript: MP IB GC VM.

**References**

1. Lynch HT, Lynch PM, Lanqua SJ, Snyder CL, Lynch JF, et al. (2009) Review of the Lynch syndrome: history, molecular genetics, screening, differential diagnosis, and medicolegal ramifications. Clin Genet 76: 1–18.
2. Ku CS, Cooper DN, Wu M, Roukos DH, Pawitan Y, et al. (2012) Gene discovery in familial cancer syndromes by exome sequencing: prospects for the elucidation of familial colorectal cancer type X. Mod Pathol 25: 1055–1068.
3. Blasco MA (2005) Telomeres and human disease: ageing, cancer and beyond. Nat Rev Genet 6: 611–622.
4. Stewart JA, Chaiken MF, Wang F, Price CM (2012) Maintaining the end: roles of telomere proteins in end-protection, telomere replication and length regulation. Mutat Res 730: 12–19.
5. Hou L, Zhang X, Gawron AJ, Liu J (2012) Surrogate tissue telomere length and cancer risk: shorter or longer? Cancer Lett 319: 130–135.
6. Alter BP, Giri N, Savage SA, Rosenberg PS (2009) Cancer in dyskeratosis congenita. Blood 113: 6549–6557.
7. Blasco MA (2005) Mice with bad ends: mouse models for the study of telomeres and telomerase. Genes Dev 19: 2621–2631.
8. Prescott J, Wentzensen IM, Savage SA, De Vivo I (2012) Epidemiologic evidence for a role of telomere dysfunction in cancer etiology. Mutat Res 730: 75–84.
9. Zee RY, Castonguay AJ, Barton NS, Buring JE (2009) Mean telomere length and risk of incident colorectal carcinoma: a prospective, nested case-control approach. Cancer Epidemiol Biomarkers Prev 18: 2280–2282.
10. Pooley KA, Sandhu MS, Tyrer J, Shah M, Driver KE, et al. (2010) Telomere length in prospective and retrospective cancer case-control studies. Cancer Res 70: 3170–3176.
11. Lee IM, Lin J, Castonguay AJ, Barton NS, Buring JE, et al. (2010) Mean leukocyte telomere length and risk of incident colorectal carcinoma in women: a prospective, nested case-control study. Clin Chem Lab Med 48: 259–262.
12. Ruzzo C, Lastella P, Ponz de Leon M, Pedroni M, Di Gregorio C, et al. (2011) Analysis of telomere dynamics in peripheral blood cells from patients with Lynch syndrome. Cancer 117: 4325–4335.
13. Maxwell F, McGlynn LM, Muir HC, Talcot D, Bonneval M, et al. (2011) Telomere attrition and decreased fetuin-A levels indicate accelerated biological aging and are implicated in the pathogenesis of colorectal cancer. Clin Cancer Res 17: 5573–5581.
14. Jones AM, Beggs AD, Carvajal-Carmona L, Farrington S, Tenesa A, et al. (2012) TERC polymorphisms are associated both with susceptibility to colorectal cancer and with longer telomeres. Gut 61: 248–254.
15. Cui Y, Cai Q, Qa S, Chow WH, Wen W, et al. (2012) Association of leukocyte telomere length with colorectal cancer risk: nested case-control findings from the Shanghai Women’s Health Study. Cancer Epidemiol Biomarkers Prev 21: 1807–1813.
16. Segui N, Pineda M, Guino E, Borras E, Navarro M, et al. (2013) Telomere length and genetic anticipation in Lynch syndrome. PLoS One 8: e61286.
17. Cavshon RM (2009) Telomere length measurement by a novel monochrome multiplex quantitative PCR method. Nucleic Acid Res 37: e21.
18. Martinez-Delgado B, Vilanova K, Inlanda-Perez L, Domingo S, Urioste M, et al. (2011) Genetic anticipation is associated with telomere shortening in hereditary breast cancer. PLoS Genet 7: e1002182.
19. Savage SA, Guadilla SM, Chanock SJ (2013) The long and short of telomeres and cancer association studies. J Natl Cancer Inst 105: 448–449.
20. Lan Q, Cavshon R, Shen M, Weinstein SJ, Virtamo J, et al. (2009) A prospective study of telomere length measured by monochrome multiplex quantitative PCR and risk of non-Hodgkin lymphoma. Clin Cancer Res 15: 7429–7433.
21. Bifuli M, Hepach CM, Griffith JK (2006) Telomeres: prognostic markers for solid tumors. Int J Cancer 119: 2255–2260.
22. Hu J, Hwang SS, Liesa M, Gan B, Sahin E, et al. (2012) Antitumor therapy provokes ALT and mitochondrial adaptive mechanisms in cancer. Cell 148: 651–663.